ESTRO 2025 - Abstract Book

S430

Clinical - Breast

ESTRO 2025

Among 480 patients ≤49 years, 476 received a TBB. In patients with a TBB and an ER+/HER2- tumour, the 10-year cumulative incidence of LR was 2.8% (95% CI, 1.4-5.0).

Conclusion: Our results strongly suggest that node-positive BC patients 50 years or older with an ER-/HER2- tumour may benefit from a tumour-bed boost.

Keywords: Tumour-bed boost, Local recurrence, Indications

References: 1.

Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. J Clin Oncol 2020;38(31):3615–25. 2. Evers J, van der Sangen MJC, van Maaren MC, et al. Radiotherapy Trends and Variations in Invasive Non-metastatic Breast Cancer Treatment in the Netherlands: A Nationwide Overview From 2008 to 2019. Clin Oncol (R Coll Radiol) 2024;S0936-6555(24)00367-4.